Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients

@article{Clemow2015AtomoxetineIP,
  title={Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients},
  author={David B Clemow and Chris J. Bushe},
  journal={Journal of Psychopharmacology},
  year={2015},
  volume={29},
  pages={1221 - 1230}
}
This article reviews data providing new insight into the trajectory of response and maintenance of response of atomoxetine in the treatment of child and adult attention-deficit hyperactivity disorder (ADHD). This nonsystematic review includes: onset of action and duration of effect, response rate, effect size, time to optimal response and norepinephrine transporter blockade biomarker data. Atomoxetine can have an onset of action within 1–2 weeks of starting treatment, but there is an… Expand
Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database
TLDR
Reductions in CAARS-Inv:SV and CGI-S scores at weeks 4 and 10 are statistically significant predictors of response to atomoxetine at later time points in adults with ADHD, but the predictors identified by these analyses are not reliable enough for use in clinical practice. Expand
Executive Functioning Outcomes Over 6 Months of Atomoxetine for Adults With ADHD: Relationship to Maintenance of Response and Relapse Over the Subsequent 6 Months After Treatment
TLDR
Treatment with atomoxetine improved EF during the treatment phases and was significantly associated with improved ADHD symptoms (Conners’ Adult ADHD Rating Scale–Investigator Rated: Screening Version [CAARS-Inv:SV]. Expand
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
TLDR
In the studies identified and assessed in this review, atomoxetine did not appear to exacerbate any of the comorbid conditions and could, therefore, be an important therapy choice for the treatment of ADHD in the presence ofComorbid disorders. Expand
Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
TLDR
Attention-deficit hyperactivity disorder symptoms improved most for ADHD and anxiety disorder combined, but presence of an anxiety disorder did not moderate any other outcomes. Expand
Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects
TLDR
Atomoxetine has been proposed as a pharmacotherapy for cocaine use disorder (CUD) and shows potential as a treatment for CUD based on its efficacy as a cognitive enhancer in other clinical populations and impact on addictive processes in preclinical and human laboratory studies. Expand
Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.
TLDR
The findings support clinical tolerability and safety and suggest potential efficacy of atomoxetine for treating ATS use disorder in this population of Participants with opioid and ATS dependence. Expand
A Signature of Attention-Elicited Electrocortical Activity Distinguishes Response From Non-Response to the Non-Stimulant Atomoxetine in Children and Adolescents With ADHD
TLDR
The N2 amplitude is a biomarker that may have utility in predicting response to atomoxetine for youth with ADHD and was able to accurately predict non-responders with a specificity of 80.8%. Expand
Adult ADHD: Future Directions for Practice and Research
TLDR
There are interesting findings regarding some drug-responsive transcripts among differentially expressed genes (DEGs) that have been suggested as potential biomarkers able to predict response to ADHD drugs, and as potential targets for the development of treatments to improve specific dimensions of ADHD phenotype. Expand
Identification of biotypes in Attention-Deficit/Hyperactivity Disorder, a report from a randomized, controlled trial
Abstract Attention-Deficit/Hyperactivity Disorder (ADHD) is a heterogeneous disorder. Current subtypes lack longitudinal stability or prognostic utility. We aimed to identify data-driven biotypesExpand
Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review
TLDR
The findings from this review indicate that persistence and adherence to atomoxetine treatment were generally high and interventions that could improve treatment adherence early in the stage of this illness to secure a better long-term prognosis are needed. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 93 REFERENCES
Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies
TLDR
Understanding the time course of children's responses to atomoxetine treatment may inform clinical decision making and also influence the durations of trials comparing the effects of this medication with other ADHD treatments. Expand
Changes in Symptoms and Adverse Events After Discontinuation of Atomoxetine in Children and Adults With Attention Deficit/Hyperactivity Disorder: A Prospective, Placebo-Controlled Assessment
TLDR
It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects, and tapering of doses is not necessary when atomxetine is discontinued. Expand
EPA-0455 – Patterns of Response to Atomoxetine for the Treatment of Adult Patients with Attention Deficit Hyperactivity Disorder
Introduction: In studies of adult patients with attention deficit hyperactivity disorder (ADHD) atomoxetine (ATX) has demonstrated substantial improvements in ADHD symptomatology using Conners’ AdultExpand
Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
Atomoxetine is a non-stimulant medication with sustained benefit throughout the day, and is a useful pharmacologic treatment option for young adults with Attention-Deficit/Hyperactivity DisorderExpand
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
TLDR
Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity. Expand
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
TLDR
A continued improvement of symptoms is expectable until 12 weeks in treatment-naïve ADHD patients treated with atomoxetine as first-line medication. Expand
Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials
TLDR
Overall, ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates. Expand
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
TLDR
In patients who responded favorably to 12 weeks of initial treatment, atomoxetine was superior to placebo in maintaining response for the ensuing 9 months, and this result supports the value of maintenance treatment with atomxetine in patients with ADHD who respond to initial treatment. Expand
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
TLDR
Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms. Expand
Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety
TLDR
Using minimum 6-week clinical trial criteria, atomoxetine may demonstrate similar efficacy to methylphenidate comparing reduction in core ADHD symptoms in meta-analysis, although the diversity of the data makes interpretation complex. Expand
...
1
2
3
4
5
...